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. A third antibody, Z2B3, was isolated 145 from a Chinese male child (donor Z) with a mild H7N9 infection in 2013; two more antibodies 146 Z2C2 and Z1A11 were isolated from this donor. Similarly, three more N9 mAbs were isolated 147 from donors W and K who were hospitalised with H7N9 virus infection (Table 1) . Antibodies 148 to H7 HA from donors Z and K are already reported .
150
Inhibitory breadth of anti-N1 NA mAbs against human H1N1 viruses
151
We focused our analysis on three mAbs: AG7C, AF9C and Z2B3 since other antibodies were 152 either of limited specificity or weaker in inhibition of NA. These three mAbs were tested for the 153 inhibition of NA activity of H1N1 viruses isolated between 1934 to 2018, in an Enzyme Linked
154
Lectin Assay (ELLA) (Figures 1, 2) , and for inhibition of the enzyme activity of the 1918 155 pandemic H1N1, and avian N1 and N9 NAs as recombinant proteins (Figure 3 ).
157
The mAbs were titrated by ELLA and the concentrations required to give 50% inhibition (IC50) 158 of NA activity were calculated by linear interpolation. The titres yielded by a 1 mg/ml solution 159 were then calculated and plotted for comparisons to control hyper-immune sheep sera 160 obtained from the National Institute for Biological Standards and Controls (NIBSC) (Figure 2,   161 3). On the secondary Y-axis, IC50 titres are shown in ng/ml.
163
AF9C inhibited the NA activities of all H1N1 viruses tested which represented the H1N1 164 viruses that have circulated in humans for over 100 years (Figures 1-3 ). AG7C showed a 165 slightly different specificity in that it was weak or failed to inhibit the NAs from 
172
Figure 2 shows that AG7C and AF9C titrate predominantly between 1:4,000 and 1:40,000 173 (IC50 ~250-25 ng/ml) on the set of viruses shown, with the exception that AG7C fails to inhibit 
203
Anti-N9 NA mAbs cross-reactive with N1 NA
204
Among six anti-N9 NA mAbs isolated from three donors exposed to H7N9 virus and tested by 205 ELLA, three inhibited recombinant N9 NA ( Figure 4 ). Two N9 NA-inhibiting mAbs were isolated 206 from donor Z, where Z2B3 was a strong inhibitor and Z2C2 was a weak inhibitor ( Figure 2A ).
207
All three mAbs from donor Z were cross-reactive with N1 NA ( Figure 4C ) and strongly inhibited 208 the H1N1pdm09 (A/England/195/2009) N1 NA ( Figure 4B ). This suggests that 6-year old 209 donor Z may have made a primary antibody response to the H1N1pdm09 N1 NA, and 210 subsequent infection with H7N9 stimulated the memory B cells to an epitope conserved 211 between N1 and N9 NAs. Notably, Z2B3 and Z2C2 have longer heavy chain CDR3 domains 212 than other mAbs and although Z2B3 and AF9C are both encoded by the same VH gene (VH1-213 69), the CDR3 amino acid sequences are significantly different.
215
Antibodies from donors W (W1C7) and K (P17C, F4C) were found to bind N9 NA in an indirect 216 immunofluorescence screen (not shown). W1C7 and F4C were specific for N9 NA, and W1C7 217 had a weak inhibitory effect in ELLA on N9 ( Figure 4 ). P17C cross-reacted with N1 NA with 218 low level of binding and showed weak inhibition by ELLA ( Figure 4B , C).
220
Antibodies from donor Z have higher numbers of amino acid substitutions in the variable 221 regions of heavy and light chains, compared to those in mAbs from other donors (Table 2) .
222
The number of substitutions in VH of mAbs Z2B3, Z2C2 and Z1A11 are 8, 13 and 17 223 respectively, whereas there are none, 1 and 1 respectively in mAbs W1C7, P17C and F4C.
224
This suggests the mAbs from donor Z are of memory B cell origin while those from donors W 225 and K resulted from de-novo responses to acute H7N9 infection.
227
Anti-NA mAbs provide prophylactic protection in vivo
228
All three of the anti-N1 NA mAbs, AG7C, AF9C and Z2B3, protected 100% of mice from 229 challenge with 10 4 TCID50 of A/PR/8/1934 virus (equivalent to 1000 LD50) when given at a 230 dose of 10 mg/kg 24 hours before infection (p<0.001; Figures 5A, B ). They prevented any 231 weight loss whereas mice that received an anti-N2 NA mAb (M6B12) succumbed to ≅20% 232 6 weight loss by day 5 and were humanely culled. An antibody to the H1 stem T1-3B (Huang 233 2015) provided a positive control for protection.
235
In another experiment, DBA/2 mice, that are uniquely susceptible to influenza infection (Pica 
240
Treated mice were protected from ≅20% weight loss (p<0.001), whereas mice receiving a 241 non-specific antibody had to be culled on days 5 or 6. One out of 6 mice in the AG7C group 242 was sacrificed on day 11 after losing >20% weight. In these prophylactic protection 243 experiments, anti-NA mAbs were as protective as T1-3B, the positive control anti-HA stalk 244 mAb (Huang et al., 2015) .
246 247

Discussion
248
We show in this paper that broadly reactive and protective antibodies to N1 NA can be isolated 249 from vaccinated and infected individuals, presumably due to the conservation in surface 250 structure between N1 NAs ( Figure 6A ). The two N1 subtype specific mAbs AG7C and AF9C 251 were isolated from the same donor who had been vaccinated in 2014 with AdimFlu-S TIV in 252 Taiwan. AG7C inhibits N1 NAs from H1N1 viruses isolated between 1918-2018. Although 253 previous investigations of subunit vaccines have found varying and usually low levels of NA 254 antigen in this case there was clearly enough to 255 induce a response.
257
The very broad reactivity of these mAbs with N1 NAs, covering the complete period of H1N1 258 virus circulation in humans, may have been induced by exposure to the significantly different 259 NA derived from the H1N1pdm09 virus. Both mAbs show significant sequence divergence 260 (Table 2) suggesting that they originated from a memory population which went through 261 multiple rounds of selection in germinal centres following previous exposures to influenza.
262
Both mAbs provided prophylactic protection in mice against the highly virulent variant of 263 A/PR/8/1934 (the Cambridge strain) (Grimm et al., 2007) and, in ultra-sensitive DBA/2 mice, 264 against infection with H1N1pdm09 X-179A (A/California/7/2009). In an earlier paper Chen et 
268
The third antibody Z2B3 was isolated from a child who experienced a mild infection with H7N9 269 virus in 2013. It was unusual in being cross-reactive with group 1 (N1) and group 2 (N9) NAs.
270
Two similar antibodies were isolated from this donor, both of which inhibited N1 NA with some 271 level of cross-reaction with N9 NA (Figure 4 ), which we interpret to imply that they were 272 selected from a subpopulation of memory cells induced previously by N1 NA. Examination of 273 the structure of the N1 and N9 NAs reveals a region of conserved surface around and within 274 the active site of the enzyme, as a possible binding site for Z2B3 ( Figure 6B ).
276
Mab Z2B3 showed good reactivity with the H1N1pdm09 virus A/England/621/2013, but poor 277 reactivity with a later clade 6B virus, A/Serbia/NS-601/2014. These two viruses showed non-278 conservative amino acid substitutions of only N386K and K432E in the head of NA (Figure  7 6C). The former site is similarly substituted in the N9 NA that Z2B3 recognizes, which suggests 280 that K432 is within the footprint of mAb Z2B3. K432 falls within a known epitope recognized 281 by anti-N9 NA antibodies (Malby et al., 1994 , Tulip et al., 1992 . The crystal structure of a N9
282
NA-mAb complex, N9-NC10, involved a contact between D56 of the antibody H-chain and 283 K432 of N9 NA (GRPKEDK; PDB 1NMB).
285
K432 was conserved prior to 2013 but underwent substitution in 2014, K432E, which became 286 dominant thereafter. We suggest that N1 NA has been under strong evolutionary pressure 287 from broadly cross-reactive antibodies induced by the H1N1pdm09 NA, that were selected 288 from memory B cells raised against NA(s) of earlier virus(es). Just as the conserved stalk of 289 HA has shown a capacity for evolution under pressure from antibody selection (Doud et al., 290 2018), the NA may similarly be forced to drift antigenically by broadly cross-reactive antibodies 291 induced by the H1N1pdm09 viruses (Gao et al., 2019) .
293
With this in mind we examined the region of the NA surface recognized by broadly reactive 294 antibodies described by Chen et al. that inhibited or bound N1 NAs of viruses isolated between 295 1918-2009 but not clade 6B H1N1pdm09 viruses (Gao et al., 2019 . Some 296 of these antibodies lost binding to N1 NAs with substitutions in a set of site-specific mutants 297 (Wan et al., 2015 , Gao et al., 2019 . Many of these antibodies also did not inhibit 298 A/Brisbane/59/2007. mAb AG7C showed a similar reactivity profile and may have been 299 affected by substitutions G249K and Q250P that are common to the non-reactive NAs. These 300 residues are exposed on the periphery of the catalytic site ( Figure 6D ). The preceding residue 301 N248 was substituted (N248D) in the H1N1pdm09 viruses isolated post 2009 and caused a 302 loss of recognition by one of the antibodies described by Chen et al. However, this substitution 303 is tolerated by mAb AG7C. There are rare natural isolates that have substituted these residues 304 (G249E/R and Q250R) indicating that even the broadly reactive mAbs can be thwarted by 305 virus antigenic drift. Further structural work to define the epitopes recognised by Z2B3, AG7C 306 and AF9C is in progress.
308
It has become clear that exposure to viruses that differ significantly from those circulating, can 309 select responses to epitopes in both HA and NA that are shared between the incoming virus 310 and the seasonal viruses in circulation, derived from the memory B cell population (Henry et 311 al., 2018) . While antibodies against new epitopes can also be generated, even in the elderly 312 , it appears that they are initially at a disadvantage but may overtake and 313 become dominant with time (Lee et al., 2019 , Henry et al., 2019 . It is these high affinity and 314 relatively specific antibodies that are mainly detected in serological surveys (Fonville et al., 
342
All subjects provided written informed consent. The list of donors with their details and isolated 343 antibodies are included in Table 1 .
345
Isolation of human monoclonal antibodies 346 Antibodies were isolated from individual humans who either received seasonal influenza 347 vaccine or were naturally infected with H7N9 virus in China or Taiwan. Antibodies were 348 isolated using single cell isolation and cloning methods as described in detail previously (Tiller 349 et al., 2008 , Smith et al., 2009 , Huang et al., 2015 , Rijal et al., 2019 . Briefly, plasmablasts in 
363
Production of NA proteins 364 Tetrameric neuraminidase proteins were expressed from constructs based on the design of 365 Xu et al. (Xu et al., 2008) . In our version the signal sequence from A/PR/8/1934 HA was 366 followed by the 15 residue tetramerization domain and thrombin site, followed by the NA 
381
For antibody inhibition measurements a dilution of the NA containing supernatant was chosen 382 that had just reached plateau activity in an ELLA. The sequences of all the constructs with 383 their identification numbers are shown in Supplementary Table 1 .
385
NA inhibition assay: Enzyme-Linked Lectin Assay (ELLA)
386
ELLA assay was adapted from the methods described by Schulman et al. (Schulman et al., 387 1968) and Sandbulte et al. (Sandbulte et al., 2009 ). This assay detects the inhibition of NA 388 enzymatic activity, cleavage of sialic acid, by anti-NA antibodies ( Figure S3 ). Viruses or 389 recombinant NA proteins were used as the source of NA. Virus growth medium was used to 390 dilute antibodies and viruses. A Nunc Immunoassay ELISA plate (Thermo Scientific 439454) 391 was plated overnight with 25 µg/ml fetuin (Sigma, F3385). Two-fold serial dilutions of sera or 392 mAbs performed in duplicates were incubated together with a fixed amount of titrated NA 393 source. Column 11 of a plate was used for NA source only control, and column 12 was used 394 for medium only control. After 2 h incubation, antibody/NA mix were transferred to the PBS 395 washed fetuin plate and incubated for 18-20 h at 37 ºC buffered by CO2 as for tissue culture.
396
Next day, the contents of the plate were discarded, and the plate washed 4 times with PBS.
397
HRP conjugated peanut agglutinin (PNA-HRP, Sigma, L7759) at 1 µg/ml was added to the 398 wells. PNA binds to the exposed galactose after cleavage of sialic acid by NA. After 1 h 
411
Mice used in protection studies, DBA/2OlaHsd mice (n=6/group) for X-179A and 412 BALB/cOlaHsd (n=6/group) for PR8 viruses were purchased from Envigo, UK and housed in 413 individually vented cages in a special unit for infectious diseases. Mice were anesthetised by 414 isofluorane (Abott) and 50 µl of virus was administrated intranasally 24 hours after the 415 intraperitoneal administration of 10 mg/kg antibody (500 µl). Mice were under regular 416 observation and weighed. Mice with weight loss ≅20 percent or morbid clinical scores were 417 euthanized by rising concentration of CO2. Non-specific IgG antibody was used as a negative 418 control. Known HA-specific antibodies were used as positive controls. Mice were infected 10 intranasally with lethal dose of viruses: X-179A (150 LD50, 10 4 TCID50) and PR8 (1000 LD50, 420 10 4 TCID50).
422
Data and Statistical analysis 423 Graphs were generated using GraphPad Prism (version 9) and Microsoft Excel 2010.
424
The ELLA titres were expressed as half maximal effective concentrations (EC50: midpoint 
665
Experiments were performed at least twice, and representative graphs are shown. The protein was kindly provided by Donald Benton (Benton et al., 2017) Figure S1. The phylogenetic tree of N1 and N9 neuraminidases used in this paper. The values on branches shows the evolutionary distances between neuraminidases. Made using MEGA7 software, muscle alignment and neighbour-joining tree settings. Figure S2 . Amino acid sequence alignment of the neuraminidases used in this paper. The numbering is not NA numbering and is only for alignment purpose. The alignment was done using BioEdit software. 
